Literature DB >> 10890227

Efficacy and potential clinical applications of Pentaglobin, an IgM-enriched immunoglobulin concentrate suitable for intravenous infusion.

R Lissner1, W G Struff, I B Autenrieth, B G Woodcock, H Karch.   

Abstract

OBJECTIVE: Characterisation of the antibodies against important human pathogens in two immunoglobulin preparations: Intraglobin F and IgM-enriched Pentaglobin.
DESIGN: In vitro assay of antibody titre using bacterial outer-membrane proteins, lipopolysaccharides (LPS), and exotoxins of clinically relevant bacteria.
METHODS: Antibody reactivities measured by ELISA and immunoblot techniques against antigens from bacteria that cause sepsis, antibiotic-resistant nosocomial pathogens, and enteric pathogens.
RESULTS: IgG anti-LPS reactivity was present in both study drugs. Specific IgM antibodies against LPS of gram-negative bacteria that cause sepsis were also detected in the IgM-enriched Pentaglobin. IgG-reactivity against gram-positive multiresistant strains of Staphylococcus aureus (S. aureus) were detectable in both preparations. IgG and IgM antibodies present against Yersinia outer proteins and Campylobacter jejuni (C. jejuni) outer membrane proteins were detected in Pentaglobin. Both preparations reacted against alpha toxin of S. aureus and streptolysin of Streptococcus pyogenes. Pentaglobin showed a strong IgM-reactivity against alpha-haemolysin.
CONCLUSION: Our data suggest that infusion of well characterised immunoglobulin preparations might be beneficial for patients with severe infections. This is highly relevant in view of the high pathogenicity of bacteria that cause infections in patients in hospital and the continually increasing antibiotic resistance (particularly methicillin-resistant S. aureus).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10890227     DOI: 10.1080/11024159950188493

Source DB:  PubMed          Journal:  Eur J Surg Suppl        ISSN: 1102-416X


  4 in total

1.  IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice.

Authors:  T Vassilev; N Mihaylova; E Voynova; M Nikolova; M Kazatchkine; S Kaveri
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  The Treatment of Severe Group A Streptococcal Infections.

Authors:  Anna Norrby-Teglund; S. Ragnar Norrby; Donald E. Low
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

3.  The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830].

Authors:  Simru Tugrul; Perihan Ergin Ozcan; Ozkan Akinci; Yalcin Seyhun; Atahan Cagatay; Nahit Cakar; Figen Esen
Journal:  Crit Care       Date:  2002-05-14       Impact factor: 9.097

4.  IgM Augments Complement Bactericidal Activity with Serum from a Patient with a Novel CD79a Mutation.

Authors:  Jeroen D Langereis; Stefanie S Henriet; Saskia Kuipers; Corry M R Weemaes; Mirjam van der Burg; Marien I de Jonge; Michiel van der Flier
Journal:  J Clin Immunol       Date:  2018-01-15       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.